Jiangsu joint drug ring China Industry Group Co., Ltd. ranked the pharmaceutical industry hundred enterprises. Group companies have the following subsidiaries: Central Pharmaceutical Co., Ltd. Jiangsu Union (2003, stock code 600513), Yangzhou Pharmaceutical Co., Ltd., Yangzhou Union Central Drug Research Center Co., Ltd., Yangzhou Pharmaceutical Import & Export Co., Ltd. joint ring , Yangzhou Lianhuan Pharmaceutical Marketing Co., Ltd., Yangzhou Young genetic engineering Alliance Central Pharmaceutical Co., Ltd., Yangzhou Pharmaceutical Co., Ltd. AllianceBernstein, bio-pharmaceutical Co., Ltd. Yangzhou Union Australia.

Group has a strong R & D capabilities, and the China Pharmaceutical University, Nanjing University, Nanjing University, Shanghai Institute of Organic Chemistry Chinese Academy of Sciences and other institutions of higher learning , research institutes, technical cooperation to build a good relationship, has a provincial center of pharmaceutical technology, innovation and technology center postdoctoral province, the provincial series of cardiovascular drugs Engineering Research Center, steroidal drugs and other research institutions.

Corporation products are steroid hormones, antibiotics, antihistamines, cardiovascular drugs, urinary tract drugs, five series, covering the chemical raw materials, intermediate body and a variety of pharmaceutical preparations. In recent years, has introduced a epristeride and epristeride tablets (Hustle), terfenadine and terfenadine tablets (Mitel), ebastine and ebastine tablets (Sudi) felodipine and felodipine tablets (Union Central Seoul set), simvastatin and simvastatin (the sign), danazol and bolt, and cetirizine hydrochloride cetirizine hydrochloride tablets (double joint) , Balofloxacin and Balofloxacin films and more than twenty drugs bulk drugs and formulations.

Group all varieties of bulk drugs and formulations are GMP certified check. Hydrocortisone, hydrocortisone acetate, hydrochloric acid, doxycycline and four other API products by the U.S. FDA inspection, doxycycline hydrochloride obtained COS certificate issued by the European EDQM. API products are sold to Europe, America, Southeast Asia, Australia and other 20 countries and regions, enjoy a good reputation.

new historical period, the company will be science and technology, product carrier, market-based, reform and innovation as the driving force, attracted talent build Heights, and actively create a win-win for employees and corporate culture of mutual trust and continue to work together with industry peers, as China's health care career development and to protect the health of people and make new contributions.